Rheumatoid arthritis sufferers have seen dramatic improvements in the standard of care over the last 25 years. Prior to the approval of methotrexate (MTX) in 1988, the best that doctors had to offer were NSAIDs and analgesics to manage pain and inflammation. As the first approved disease modifying drug, MTX revolutionized RA treatment and is […]
LXRX – Lexicon Pharmaceuticals is Overvalued
Lexicon Pharma stocks its drug candidate pipeline with a discovery platform based on mouse gene knockout technology, which has allowed them to study the roles of different proteins in disease and select drug targets accordingly. The company’s major clinical programs are headlined by their candidate for type 2 diabetes, LX4211. LXRX has consistently talked about […]
PFE & BMY – The anticoagulant market & the Apixaban Catalyst
Background: The market for anti-thrombosis agents is set for dramatic changes. A thrombus is an aggregation of platelets which plays a key part in several life-threatening diseases, such as myocardial infarction, stroke, deep-vein thrombosis, pulmonary embolism, stent thrombosis, as well as other medical conditions. The market for therapies against thrombosis can be broken down simply […]
AstraZeneca- How Much Longer Can It Go On?
A great article in the Wall Street Journal by Hester Plumridge AstraZeneca’s Too-Concentrated Solution talks about the company’s sale today of its medical devices unit AstraTech to Dentsply International. With the sale, AstraZeneca is focusing its resources the core prescription drugs business. This doesn’t sound like a good plan considering AstraZeneca doesn’t exactly have the […]
